Norethindrone acetate Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

An industry-sponsored clinical trial by Sumitomo Pharma Switzerland GmbH investigates clinical parameters related to norethindrone acetate in conditions including pregnancy-related disorders, pregnancy complications, and high-risk pregnancy. Currently classified as not yet recruiting, this observational study lacks a specified interventional phase and utilizes administrative healthcare data to evaluate pregnancy outcomes. Overall, this research reflects a targeted effort to assess reproductive health endpoints in specialized patient cohorts.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05739136	Not yet recruiting	Pregnancy Related\|Pregnancy Complications\|Pregnancy High Risk	Sumitomo Pharma Switzerland GmbH	2025-01	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Norethindrone acetate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Norethindrone acetate selectively binds to intracellular progesterone receptors to suppress hypothalamic-pituitary-ovarian signaling and decrease gonadotropin release, thereby inhibiting ovulation and modulating endometrial differentiation. This progestational receptor activation and cellular tissue regulation provide the biochemical foundation for managing reproductive conditions and evaluating pregnancy-related outcomes in clinical studies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).